Literature DB >> 23897824

SHANK3 gene mutations associated with autism facilitate ligand binding to the Shank3 ankyrin repeat region.

Marie Germaine Mameza1, Elena Dvoretskova, Margarete Bamann, Hans-Hinrich Hönck, Türkan Güler, Tobias M Boeckers, Michael Schoen, Chiara Verpelli, Carlo Sala, Igor Barsukov, Alexander Dityatev, Hans-Jürgen Kreienkamp.   

Abstract

Shank/ProSAP proteins are major scaffold proteins of the postsynaptic density; mutations in the human SHANK3 gene are associated with intellectual disability or autism spectrum disorders. We have analyzed the functional relevance of several SHANK3 missense mutations affecting the N-terminal portion of the protein by expression of wild-type and mutant Shank3 in cultured neurons and by binding assays in heterologous cells. Postsynaptic targeting of recombinant Shank3 was unaltered. In electrophysiological experiments, both wild-type and L68P mutant forms of Shank3 were equally effective in restoring synaptic function after knockdown of endogenous Shank3. We observed that several mutations affected binding to interaction partners of the Shank3 ankyrin repeat region. One of these mutations, L68P, improved binding to both ligands. Leu-68 is located N-terminal to the ankyrin repeats, in a highly conserved region that we identify here as a novel domain termed the Shank/ProSAP N-terminal (SPN) domain. We show that the SPN domain interacts with the ankyrin repeats in an intramolecular manner, thereby restricting access of either Sharpin or α-fodrin. The L68P mutation disrupts this blockade, thus exposing the Shank3 ankyrin repeat region to its ligands. Our data identify a new type of regulation of Shank proteins and suggest that mutations in the SHANK3 gene do not necessarily induce a loss of function, but may represent a gain of function with respect to specific interaction partners.

Entities:  

Keywords:  Ankyrin Repeats; Autism; Genetic Diseases; Mutant; PDZ Domain; Postsynaptic Density; Scaffold Proteins; Synapses

Mesh:

Substances:

Year:  2013        PMID: 23897824      PMCID: PMC3772216          DOI: 10.1074/jbc.M112.424747

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  NPS@: network protein sequence analysis.

Authors:  C Combet; C Blanchet; C Geourjon; G Deléage
Journal:  Trends Biochem Sci       Date:  2000-03       Impact factor: 13.807

2.  Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain.

Authors:  H Zitzer; H H Hönck; D Bächner; D Richter; H J Kreienkamp
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

3.  Sharpin, a novel postsynaptic density protein that directly interacts with the shank family of proteins.

Authors:  S Lim; C Sala; J Yoon; S Park; S Kuroda; M Sheng; E Kim
Journal:  Mol Cell Neurosci       Date:  2001-02       Impact factor: 4.314

4.  The backbone of the post-synaptic density originated in a unicellular ancestor of choanoflagellates and metazoans.

Authors:  Alexandre Alié; Michaël Manuel
Journal:  BMC Evol Biol       Date:  2010-02-03       Impact factor: 3.260

5.  Shank1 mRNA: dendritic transport by kinesin and translational control by the 5'untranslated region.

Authors:  Katrin Falley; Janin Schütt; Peter Iglauer; Katharina Menke; Christoph Maas; Matthias Kneussel; Stefan Kindler; Fred S Wouters; Dietmar Richter; Hans-Jürgen Kreienkamp
Journal:  Traffic       Date:  2009-04-11       Impact factor: 6.215

Review 6.  ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease.

Authors:  Tobias M Boeckers; Jürgen Bockmann; Michael R Kreutz; Eckart D Gundelfinger
Journal:  J Neurochem       Date:  2002-06       Impact factor: 5.372

7.  SHARPIN is an endogenous inhibitor of β1-integrin activation.

Authors:  Juha K Rantala; Jeroen Pouwels; Teijo Pellinen; Stefan Veltel; Petra Laasola; Elina Mattila; Christopher S Potter; Ted Duffy; John P Sundberg; Olli Kallioniemi; Janet A Askari; Martin J Humphries; Maddy Parsons; Marko Salmi; Johanna Ivaska
Journal:  Nat Cell Biol       Date:  2011-09-25       Impact factor: 28.824

8.  Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication.

Authors:  Ozlem Bozdagi; Takeshi Sakurai; Danae Papapetrou; Xiaobin Wang; Dara L Dickstein; Nagahide Takahashi; Yuji Kajiwara; Mu Yang; Adam M Katz; Maria Luisa Scattoni; Mark J Harris; Roheeni Saxena; Jill L Silverman; Jacqueline N Crawley; Qiang Zhou; Patrick R Hof; Joseph D Buxbaum
Journal:  Mol Autism       Date:  2010-12-17       Impact factor: 7.509

9.  SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism.

Authors:  C M Durand; J Perroy; F Loll; D Perrais; L Fagni; T Bourgeron; M Montcouquiol; N Sans
Journal:  Mol Psychiatry       Date:  2011-05-24       Impact factor: 15.992

10.  Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor-mediated long-term depression.

Authors:  Peter R Moult; Clare M Gladding; Thomas M Sanderson; Stephen M Fitzjohn; Zafar I Bashir; Elek Molnar; Graham L Collingridge
Journal:  J Neurosci       Date:  2006-03-01       Impact factor: 6.167

View more
  28 in total

1.  Autism-associated SHANK3 missense point mutations impact conformational fluctuations and protein turnover at synapses.

Authors:  Michael Bucher; Stephan Niebling; Yuhao Han; Dmitry Molodenskiy; Fatemeh Hassani Nia; Hans-Jürgen Kreienkamp; Dmitri Svergun; Eunjoon Kim; Alla S Kostyukova; Michael R Kreutz; Marina Mikhaylova
Journal:  Elife       Date:  2021-05-04       Impact factor: 8.140

Review 2.  Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.

Authors:  Hala Harony-Nicolas; Silvia De Rubeis; Alexander Kolevzon; Joseph D Buxbaum
Journal:  J Child Neurol       Date:  2015-09-08       Impact factor: 1.987

Review 3.  SHANK proteins: roles at the synapse and in autism spectrum disorder.

Authors:  Patricia Monteiro; Guoping Feng
Journal:  Nat Rev Neurosci       Date:  2017-02-09       Impact factor: 34.870

Review 4.  Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications.

Authors:  Jan Philipp Delling; Tobias M Boeckers
Journal:  J Neurodev Disord       Date:  2021-11-16       Impact factor: 4.025

Review 5.  Genetic Findings as the Potential Basis of Personalized Pharmacotherapy in Phelan-McDermid Syndrome.

Authors:  Brianna Dyar; Erika Meaddough; Sara M Sarasua; Curtis Rogers; Katy Phelan; Luigi Boccuto
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

6.  Altered Striatal Synaptic Function and Abnormal Behaviour in Shank3 Exon4-9 Deletion Mouse Model of Autism.

Authors:  Thomas C Jaramillo; Haley E Speed; Zhong Xuan; Jeremy M Reimers; Shunan Liu; Craig M Powell
Journal:  Autism Res       Date:  2015-11-11       Impact factor: 5.216

Review 7.  Association of SHANK Family with Neuropsychiatric Disorders: An Update on Genetic and Animal Model Discoveries.

Authors:  Lily Wan; Du Liu; Wen-Biao Xiao; Bo-Xin Zhang; Xiao-Xin Yan; Zhao-Hui Luo; Bo Xiao
Journal:  Cell Mol Neurobiol       Date:  2021-02-17       Impact factor: 5.046

Review 8.  SHARPIN: Role in Finding NEMO and in Amyloid-Beta Clearance and Degradation (ABCD) Pathway in Alzheimer's Disease?

Authors:  Dhanya Krishnan; Ramsekhar N Menon; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2021-01-05       Impact factor: 5.046

9.  Association of SHANK3 Gene Polymorphism and Parkinson Disease in the North of Iran.

Authors:  Nahid Mizban; Nasim Vousooghi; Nasrin Mizban
Journal:  Basic Clin Neurosci       Date:  2021-01-01

10.  A recurrent SHANK1 mutation implicated in autism spectrum disorder causes autistic-like core behaviors in mice via downregulation of mGluR1-IP3R1-calcium signaling.

Authors:  Yue Qin; Yasong Du; Liqiang Chen; Yanyan Liu; Wenjing Xu; Ying Liu; Ying Li; Jing Leng; Yalan Wang; Xiao-Yong Zhang; Jianfeng Feng; Feng Zhang; Li Jin; Zilong Qiu; Xiaohong Gong; Hongyan Wang
Journal:  Mol Psychiatry       Date:  2022-04-06       Impact factor: 13.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.